Interleukin-7
Also known as: CYT-007, CYT107, IL-7, Lymphopoietin-1, NT-I7, rhIL-7, rhIL-7-hyFc
Source Interleukin-7 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Interleukin‑7 (IL‑7) is a cytokine that supports the development, survival and homeostatic proliferation of lymphocytes. It is being investigated as an immunomodulatory agent to counteract age‑related immune decline and to augment immune competence in various settings. IL‑7 is not yet approved for any therapeutic indication and remains an investigational compound studied primarily in pre‑clinical models and early‑phase research.
Mechanism of Action
IL‑7 binds to the heterodimeric IL‑7 receptor composed of the IL‑7Rα chain and the common γ‑chain. This engagement triggers intracellular signaling pathways that promote survival, proliferation, and maintenance of naïve and memory T cells, as well as early B‑cell development. By sustaining lymphocyte numbers and function, IL‑7 helps preserve immune homeostasis, a process highlighted in studies of immunosenescence.
What the Research Shows
A 2017 review highlighted IL‑7’s central role in maintaining immune healthspan and suggested that modulating its activity could mitigate immunosenescence. A 2020 trans‑ethnic GWAS of 746,667 individuals identified a missense IL7 variant in South Asians that influences peripheral lymphocyte counts and in‑vitro IL‑7 secretion, underscoring a genetic link between IL‑7 signaling and blood‑cell traits. A 2020 cancer‑focused review described immunosenescence as a driver of tumor progression and noted recombinant IL‑7 as a potential senescence‑targeting intervention. A 2022 comprehensive review of IL‑7 was listed, but its abstract provided no additional data. Collectively, the literature points to IL‑7’s importance in lymphocyte biology and its investigational use for immune rejuvenation, though clinical evidence remains limited.
Reported Benefits
Pre‑clinical and observational data suggest that IL‑7 can increase circulating lymphocyte numbers, improve T‑cell survival, and potentially restore aspects of immune function that decline with age. Genetic studies linking IL‑7 variants to higher lymphocyte counts support its role in hematopoiesis. These properties raise the prospect of using IL‑7 to enhance vaccine responses, reduce infection risk in older adults, or support immune recovery after lymphodepleting therapies.
Limitations of the Evidence
Evidence for therapeutic benefit is largely indirect, derived from animal models, mechanistic reviews, and population genetics; no randomized clinical trials are cited. The impact of IL‑7 on cancer outcomes or autoimmune risk remains ambiguous, and the optimal dosing, timing, and patient populations are undefined. Moreover, the cited literature does not address long‑term safety or efficacy, leaving substantial gaps before clinical application.
Safety Considerations
The abstracts do not report specific adverse events associated with IL‑7 administration, and safety data from human trials are not presented. As an investigational cytokine, potential risks may include excessive lymphocyte proliferation, cytokine‑related inflammation, or off‑target immune activation. Until formal clinical safety assessments are published, caution is warranted, and IL‑7 should be used only within regulated research protocols.
How It Is Administered
IL‑7 has been formulated for parenteral delivery and can be administered by subcutaneous, intramuscular, or intravenous injection. Formulations used in research settings are typically recombinant proteins or fusion constructs designed for extended half‑life. Specific dosing regimens and schedules are defined by individual study protocols and are not standardized.
Routes of Administration
Goals & Uses
- HIV-associated immune deficiencyInfectious Disease / ImmunologyModerate
- Sepsis-induced lymphopenia reversalCritical Care / ImmunologyModerate
- Graft-versus-host disease mitigation post-HSCTTransplant ImmunologyLow
- immune reconstitutionImmunologyModerate
- Cancer immunotherapy augmentationOncologyLow
- Cancer immunotherapyOncologyModerate
- Vaccine immune response enhancementVaccinologyLow
- T-cell immune reconstitutionImmunologyModerate
Contraindications
- Autoimmune diseaseImmuneModerateMay worsen or interact with immune-mediated disease
- Hypersensitivity to IL-7 or excipientsAllergy / ImmunologyHigh
- Active graft-versus-host diseaseTransplant ImmunologyHigh
- Uncontrolled systemic infectionInfectious DiseaseModerate
- Hematologic malignancy with T-cell lineage involvementOncologyHigh
- Active autoimmune diseaseAutoimmunityHigh
- severe lymphoproliferative disordersHematologyHigh
Adverse Effects
- Skin rash / eosinophiliaDermatologic / HematologicUncommon
- lymphocytosisLaboratoryCommon
- Flu‑like symptomsSystemicUncommon
- Injection site reactionsLocalCommon
- ThrombocytopeniaHematologicUncommonLow platelet count
- Autoimmune manifestationsImmunologicRare
- Transient lymphadenopathyLymphaticCommon
- Flu-like symptoms / feverSystemicCommon
- Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
Drug Interactions
- Checkpoint inhibitors (e.g., pembrolizumab, nivolumab)Moderate
- JAK inhibitors (e.g., ruxolitinib, tofacitinib)High
- Immunosuppressants (e.g., tacrolimus, cyclosporine)Moderate
- CorticosteroidsModerate
- calcineurin inhibitors (e.g., tacrolimus)Moderate
Population Constraints
- Patients with T-cell malignanciesOncologyAbsolute
- Pediatric patientsAgeRelative
- Patients with pre-existing autoimmune diseaseAutoimmuneRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Elderly patients (>65 years)AgeRelative
- Pregnant womenReproductiveAbsolute
Regulatory Status
- European UnionInvestigationalClinical trial authorization granted for immune reconstitution studies.
- United StatesInvestigationalIND in place for HIV and oncology trials.
- United KingdomInvestigationalNo MHRA-approved IL-7 therapeutic product; clinical trial access only as of 2024.
Not approved for clinical use; currently in Phase I/II trials for HIV, cancer, and post‑transplant immune recovery.
Evidence & Sources
- Journal ArticleModerateNguyen V, Mendelsohn A, Larrick JW2017-01-01T00:00:00.000000Z
- Journal ArticleHighChen MH, et al.2020-01-01T00:00:00.000000Z
- Journal ArticleModerateLian J, et al.2020-01-01T00:00:00.000000Z
- Journal ArticleModerateWiner H, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleModerateSmolinska S, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateKittipatarin C, Khaled AR2007-01-01T00:00:00.000000Z
Frequently Asked Questions
What is the primary biological role of IL‑7?
IL‑7 is essential for the development, survival, and homeostatic proliferation of T cells and early B‑cell precursors. By engaging its receptor, it activates signaling pathways that maintain lymphocyte numbers and functional competence.
Has IL‑7 been approved for any medical use?
No. IL‑7 is classified as an investigational cytokine and currently has no regulatory approval for therapeutic indications. Its use is confined to experimental studies and clinical trials.
Can IL‑7 improve immune function in older adults?
Pre‑clinical and observational evidence indicates that IL‑7 can boost lymphocyte counts and may counteract age‑related immune decline, but definitive clinical trials demonstrating efficacy in older populations are lacking.
What are the known risks of giving IL‑7 to patients?
Published abstracts do not detail adverse events. Potential risks, inferred from cytokine biology, include excessive immune activation, inflammation, or abnormal lymphocyte expansion. Safety must be established in controlled trials.
How is IL‑7 typically delivered in research studies?
Research formulations of IL‑7 are administered by injection—subcutaneously, intramuscularly, or intravenously—using recombinant protein or fusion constructs designed for stability and appropriate pharmacokinetics.
What is Interleukin-7 used for?
Interleukin-7 is educationally associated with: HIV-associated immune deficiency, Sepsis-induced lymphopenia reversal, Graft-versus-host disease mitigation post-HSCT, immune reconstitution, Cancer immunotherapy augmentation, Cancer immunotherapy, Vaccine immune response enhancement, T-cell immune reconstitution. Educational only — not medical advice.
How is Interleukin-7 administered?
Recorded routes of administration: Intramuscular, Intravenous, Subcutaneous.
What are the potential side effects of Interleukin-7?
Reported adverse effects include: Skin rash / eosinophilia, lymphocytosis, Flu‑like symptoms, Injection site reactions, Thrombocytopenia, Autoimmune manifestations, Transient lymphadenopathy, Flu-like symptoms / fever, Injection site reaction. This list is not exhaustive — consult a qualified clinician.
Who should avoid Interleukin-7?
Recorded contraindications: Autoimmune disease, Hypersensitivity to IL-7 or excipients, Active graft-versus-host disease, Uncontrolled systemic infection, Hematologic malignancy with T-cell lineage involvement, Active autoimmune disease, severe lymphoproliferative disorders. Consult a qualified clinician before use.